Other languages Sensei Biotherapeutics, Inc.

Equities

SNSE

US81728A1088

Market Closed - Nasdaq Other stock markets 04:30:01 2024-04-26 pm EDT			5-day change	1st Jan Change
1.02 ^USD	+1.99%		+5.15%	+47.40%

Apr. 24	Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	CI
Apr. 04	Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting	Apr. 24
Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of Vista Within the Tumor Microenvironment	Apr. 04
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 28
Sensei Biotherapeutics, Inc. Announces Management Changes	Feb. 08
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 07
Newtyn Partners, LP and Newtyn TE Partners, LP, managed by Newtyn Management, LLC cancelled the acquisition of remaining 93.48% stake in Sensei Biotherapeutics, Inc..	Nov. 05
Sensei Biotherapeutics, Inc. Appoints Stephanie Krebs, Ms, Mba, as Chief Business Officer	Nov. 01
Sensei Biotherapeutics, Inc. to Present Initial Clinical Data from Dose Escalation Trial of SNS 101 At 2023 SITC Annual Meeting	23-10-25
Sensei Biotherapeutics Doses First Patient in Combination Study of SNS-101 With Libtayo	23-09-27
Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron's Libtayo	23-09-27
Sensei Biotherapeutics, Inc. Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action	23-09-21
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023	23-08-03
Sensei Biotherapeutics, Inc. Announces First Patient Dosed in Phase 1/2 Clinical Trial of SNS-101	23-06-01
Sensei Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Sector Update: Health Care Stocks Weaker Late Afternoon	23-04-20
Sector Update: Health Care Stocks Dropping Thursday Afternoon	23-04-20
Sensei Biotherapeutics Says US FDA Approves Investigational New Drug Application for Cancer Drug Candidate SNS-101	23-04-20
Sensei Biotherapeutics, Inc. Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for SNS-101, a Conditionally Active Vista-Blocking Antibody	23-04-20
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-28
Sensei Biotherapeutics Confirms the Receipt of Nominations from Apeiron Investment Group	23-03-10

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

SENSEI BIOTHERAPEUTICS : Mixed Q3; but cash cushion remains intact

November 10, 2022 at 06:59 am EST